Long COVID Clinical Trial
Official title:
RECOVER-ENERGIZE: A Platform Protocol for Evaluation of Interventions for Exercise Intolerance in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). The focus of this protocol is to assess interventions that can improve exercise capacity, daily activities tolerance, and quality of life in patients with PASC.
Status | Not yet recruiting |
Enrollment | 300 |
Est. completion date | January 2026 |
Est. primary completion date | October 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | • See NCT06404047 for RECOVER-ENERGIZE: Platform Protocol level inclusion and exclusion criteria which applies to this appendix Additional Appendix B (Structured Pacing (PEM)) Level Inclusion Criteria: 1. Participant identifies new PEM following a SARS-CoV-2 infection that has persisted for at least 12 weeks and is still present at the time of consent 2. Score of 2 or greater for both frequency and severity for any of the first 5 questions on the Screening mDSQ-PEM AND Answer of YES to either item 7 or 8 on Screening mDSQ-PEM, or response of >14 h in item 9. Additional Appendix B (Structured Pacing (PEM)) Level Exclusion Criteria: 1. Inability to attend in-person screening visit or participate in weekly visits (in-person [= 1] and remote) 2. Participant was previously enrolled in Appendix A of this protocol and has NOT completed the full study follow-up period of Appendix A |
Country | Name | City | State |
---|---|---|---|
United States | All sites listed under NCT06404047 | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in frequency of PEM symptoms, as measured by the Modified DePaul Symptom - Post-Exertional Malaise questionnaire (mDSQ-PEM) | Symptom frequency is rated on a 5-point Likert scale: 0 = none of the time, 1 = a little of the time, 2 = about half the time, 3 = most of the time, and 4 = all of the time. | Baseline, week 12 (End Of Intervention (EOI)), month 6 (End of Study (EOS)) | |
Primary | Change in severity of PEM symptoms, as measured by the Modified DePaul Symptom - Post-Exertional Malaise questionnaire (mDSQ-PEM) | Symptom severity is rated on a 5-point Likert scale: 0 = symptom not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. | Baseline, week 12 (EOI), month 6 (EOS) | |
Primary | Change in duration of PEM symptoms, as measured by the Modified DePaul Symptom - Post-Exertional Malaise questionnaire (mDSQ-PEM) | Baseline, week 12 (EOI), month 6 (EOS) | ||
Secondary | Change in PASC symptoms, as measured by the PASC Symptom Questionnaire | The PASC Symptom Questionnaire is a 33-question survey for self-reporting multiple PASC-related symptoms across multiple systems. | Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS) | |
Secondary | Change in PASC symptoms, as measured by the PROMIS-Cog Questionnaire | The PROMIS Short Form v.2.0 - Cognitive Function 8a (PROMIS-Cog) is the PROMIS Short Form to assess cognitive function and is a self-report, 8-item questionnaire targeting cognitive function in the past seven days. | Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS) | |
Secondary | Change in quality of life, as measured by the PROMIS-29+2 | The PROMIS-29+2 is used to calculate a preference score (PROPr) by the addition of two Cognitive Function Ability items. Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health). | Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS) | |
Secondary | Change in quality of life, as measured by the EQ-5D 5L | The EQ-5D is a standardized measure of health status. | Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS) | |
Secondary | Change in physical activity, as measured by Actigraphy | Actigraphy will be measured by Fitbit. | Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS) | |
Secondary | Change in physical activity, as measured by the PROMIS SF-Physical Function (PROMIS-PF) | The PROMIS Short Form v2.0 - Physical Function 8b (PROMIS-PF) consists of 8 items. The PROMIS Physical Function instruments measure self-reported capability rather than actual performance of physical activities. | Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS) | |
Secondary | Change in orthostatic hypotension, as measured by the Modified Orthostatic Hypotension Questionnaire (mOHQ) | The Orthostatic Hypotension Questionnaire (OHQ) is a measure of orthostatic intolerance. The modified OHQ (mOHQ) measure used in this study includes a total of ten items related to daily activities and symptoms. | Screening, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05926505 -
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Completed |
NCT05552612 -
Health-related Quality of Life and Long COVID
|
||
Completed |
NCT05531019 -
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A
|
N/A | |
Not yet recruiting |
NCT04949386 -
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
|
Phase 2 | |
Recruiting |
NCT06118112 -
Living With Long COVID: LONGCOVID-EXPERIENCE
|
||
Completed |
NCT05185674 -
Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
|
||
Active, not recruiting |
NCT05965752 -
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
|
N/A | |
Active, not recruiting |
NCT05965739 -
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
|
N/A | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Recruiting |
NCT05606211 -
Pain in Long COVID-19: The Role of Sleep
|
||
Active, not recruiting |
NCT05713266 -
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
|
||
Completed |
NCT05679505 -
Vagus Nerve Stimulation for Post-COVID Syndrome
|
N/A | |
Completed |
NCT05601180 -
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
|
N/A | |
Not yet recruiting |
NCT06045338 -
Mind Body Intervention for Long COVID
|
N/A | |
Recruiting |
NCT06091358 -
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
|
N/A | |
Recruiting |
NCT05566392 -
Longterm Influence of Pediatric Long COVID Syndrome
|
||
Recruiting |
NCT05855369 -
Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss
|
Phase 2/Phase 3 | |
Recruiting |
NCT05572346 -
Digital App for Telerehabilitation in Respiratory Diseases
|
||
Recruiting |
NCT06316843 -
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
|
Phase 2 |